OssDsign Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

OssDsign şirketinin kazançları yıllık ortalama -8.8% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 21.2% oranında artan oldu. Gelirler yıllık ortalama 42.6% oranında artan oldu.

Anahtar bilgiler

-8.8%

Kazanç büyüme oranı

36.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	6.2%
Gelir büyüme oranı	42.6%
Özkaynak getirisi	-50.6%
Net Marj	-92.2%
Sonraki Kazanç Güncellemesi	04 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 23

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

Aug 06

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

Mar 19

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

Gelir ve Gider Dağılımı

OssDsign nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:OSSD Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	123	-114	149	26
31 Mar 24	118	-118	145	27
31 Dec 23	112	-130	143	29
30 Sep 23	97	-109	131	29
30 Jun 23	83	-95	113	40
31 Mar 23	71	-99	142	8
31 Dec 22	57	-99	113	25
30 Sep 22	46	-96	111	17
30 Jun 22	38	-93	115	0
31 Mar 22	33	-95	107	0
31 Dec 21	32	-94	104	0
30 Sep 21	29	-90	100	0
30 Jun 21	27	-92	100	0
31 Mar 21	23	-90	94	0
31 Dec 20	25	-85	92	0
30 Sep 20	24	-89	96	0
30 Jun 20	22	-89	97	0
31 Mar 20	22	-85	94	0
31 Dec 19	18	-84	90	0
30 Sep 19	18	-72	80	0
30 Jun 19	20	-66	73	0
31 Mar 19	21	-62	68	0
31 Dec 18	21	-56	63	0
31 Dec 17	16	-63	52	0

Kaliteli Kazançlar: OSSD şu anda kârlı değil.

Büyüyen Kar Marjı: OSSD şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: OSSD kârlı değildir ve zararlar son 5 yılda yılda 8.8% oranında artmıştır.

Büyüme Hızlandırma: OSSD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: OSSD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 28.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: OSSD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -50.61% ) sahiptir.

OssDsign Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS misses analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 30%, revenue upgraded

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Consensus EPS estimates fall by 15%

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to kr14.00

Insufficient new directors

Consensus revenue estimates fall by 16%

Chief Executive Officer recently bought kr133k worth of stock

Chief Executive Officer recently bought kr133k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Chief Executive Officer recently bought kr124k worth of stock

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Independent Chairman of the Board recently bought kr150k worth of stock

Consensus EPS estimates increase to -kr3.00

Price target decreased to kr17.33

Chief Executive Officer recently bought kr210k worth of stock

Chief Executive Officer recently bought kr388k worth of stock

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

Chief Financial Officer recently bought kr214k worth of stock

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.